Allergy Therapeutics Share Chat (AGY)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Allergy Therapeutics Plc	LSE:AGY	London	Ordinary Share	GB00B02LCQ05	ORD 0.1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	11.75p	11.50p	12.00p	11.75p	11.75p	11.75p	5,025,943	08:00:00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	68.3	-6.9	-1.3	-	76

Allergy Therapeutics Share Discussion Threads

Showing 3826 to 3850 of 3850 messages

Chat Pages: 154 153 152 151 150 149 148 147 146 145 144 143 Older

Date	Subject	Author	Discuss
01/8/2019 15:52	Brexit nerves impacting?	jimmyloser	Read Full Thread Reply
17/7/2019 18:38	... But not quite enough to top up...	ewanwhose	Read Full Thread Reply
17/7/2019 11:45	Bit of a sharp pull back....	audigger	Read Full Thread Reply
11/7/2019 07:21	Video from FD Nick Wykeman re: this mornings trading update: hTTps://youtu.be/SvjBtruZ528	macc1	Read Full Thread Reply
27/6/2019 14:24	Looks almost back to where we started yesterday. Disappointing end to the day	richsawko	Read Full Thread Reply
27/6/2019 10:50	Didn't see that coming. Certainly reinforces the belief that the management team are on top of things. Proving to be a bit of a roller coaster ride this year! What would be impressive is if they can pull a rabbit out of the hat with a more favourable interpretation of the B301 Phase III trial for the birch product.	audigger	Read Full Thread Reply
27/6/2019 08:03	Plenty of cash and can we dare hope for a bottom-line profit?	ewanwhose	Read Full Thread Reply
27/6/2019 07:15	Breaking news Allergy Therapeutics plc ("Allergy Therapeutics", "ATL" or the "Group") Successful litigation settlement relating to PQ Grass Phase II Trial 27 June 2019 Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it has received a $7.6m settlement from Inflamax Research Inc. ("Inflamax") in relation to legal proceedings about the previously disclosed inconclusive Phase II Grass MATA MPL trial which took place in the USA in 2015-16. Inflamax has also agreed to pay a substantial part of the Group's legal costs. The clinical trial (G204) used mobile challenge chambers provided by Inflamax and preceded the successful Grass MATA MPL trial (G205) which the Group reported in June 2018. The Group commenced legal proceedings in the English High Court against Inflamax in March 2017 for breach of contract and misrepresentation concerning the G204 Study. Commenting on outcome, Manuel Llobet, CEO of Allergy Therapeutics, said: "ATL has always had full confidence in the Grass MATA MPL product and maintained that the inconclusive results of the G204 study were due to the inadequate procedures in the study. I am pleased that Inflamax have now compensated ATL for a significant proportion of the wasted study costs, as well as agreeing to pay the majority of the legal costs. Allergy Therapeutics aims to maintain the highest standards throughout its business and we are pleased that the matter has now been resolved."	jimmyloser	Read Full Thread Reply
25/6/2019 11:25	About time Skygem topped up.	ewanwhose	Read Full Thread Reply
14/6/2019 08:19	On Thursday Liu Xiaoming, China's ambassador to the UK, said that excluding Huawei from Britain's 5G network would "send a very bad signal". However, weak sterling gives Chinese investors an opportunity to buy more UK assets, says Monique Wong of Coutts. Chinese investment in the UK has largely been focused on the commercial property sector - "the iconic Cheesegrater was sold to Chinese investors a couple of years ago for just over a billion pounds", she says. "And don't forgot sterling is cheap, " she said, about 10% cheaper against the Chinese currency since the referendum. "It is an opportunity for Chinese investors and international investors more broadly," she said, adding that China's Fosun has expressed an interest in buying Thomas Cook's tour business. She also had a view on why was the market impact of the Hong Kong protests was limited - the Hang Seng stock index was down less than 0.5%. She said: "Usually the protests blow over... it doesn't really change our view on the region".	jimmyloser	Read Full Thread Reply
11/6/2019 13:45	@jimmyloser Is Woodford buying in? If he was, the price would nosedive: maybe he's shorting it?	andrewbaker	Read Full Thread Reply
11/6/2019 07:03	See above......Somebody likes the taste of peanuts. 15% of AGY for circa 11p a share !!!	jimmyloser	Read Full Thread Reply
07/6/2019 10:49	Here we go again....are the Chinese investors looking for more than peanuts?	jimmyloser	Read Full Thread Reply
06/6/2019 11:07	Chinese peanuts!	jimmyloser	Read Full Thread Reply
05/6/2019 17:35	Well done Jimmy, very funny!!! :-)	nquaile875	Read Full Thread Reply
05/6/2019 15:46	Is Woodford buying in?	jimmyloser	Read Full Thread Reply
03/6/2019 19:19	A few positive words on peanuts over the next few days would not go amiss.	jimmyloser	Read Full Thread Reply
03/6/2019 12:39	Good to see some buying today. Can't see any news anywhere.	ewanwhose	Read Full Thread Reply
20/5/2019 07:22	Indeed thew mention of China appears a new line form the PR gurus they employ. Encouraging but early days yet and we know how perilous the journey can be. Would be good if it gave the share price another small jolt north	audigger	Read Full Thread Reply
20/5/2019 07:06	A little encouraging news this morning from AGY and am I alone in noting the CHINA gets a first mention as a potential market?	jimmyloser	Read Full Thread Reply
15/5/2019 13:41	Hmm....I wonder what is going on? Wonder what the detailed history is of ZQ investments internationally over time?	blather1	Read Full Thread Reply
15/5/2019 13:24	There is a hierarchy of ZQ companies who own a hierarchy of Skygem companies - they are listed in the RNS	ewanwhose	Read Full Thread Reply
15/5/2019 13:16	So a total of close to 30% of all AGY shares were snapped up in three (think it was three) momentous buys on one day and only part of those trades were accounted for by ZQ as mentioned in the RNS. Is Skygem and ZQ the same entity?	blather1	Read Full Thread Reply
15/5/2019 12:32	I've been wondering this as well. 500M shares were traded (ie 250M bought and 250M sold). Skygem declared ~76M. In the absence of another declaration, it would seem that all the shares bought by Skygem were bought by another entity (not a MM) and passed on the same day. It could be a way of hiding the true purchaser, somebody taking a cut or somebody wanting to bump up their trading volumes.	ewanwhose	Read Full Thread Reply
15/5/2019 12:24	Skygem Acquisitions is a subsidiary of Skygem Holdings and the only thing it has done is buy AGY shares. The name just seems a bit too obvious - do they really plan to 'acquire' all of AGY or just make it look like they want to?	ewanwhose	Read Full Thread Reply

Chat Pages: 154 153 152 151 150 149 148 147 146 145 144 143 Older

Your Recent History

LSE

AGY

Allergy Th..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.